Aggregate Fiscal Impact of COVID-19

10.1596/36607 ◽  
2021 ◽  
Author(s):  
Keyword(s):  
Fiscal Impact

The Clinical and Fiscal Impact of Endovascular Repair of Abdominal Aortic Aneurysms

2004 ◽  
Vol 7 (5) ◽  
pp. E503-E507 ◽  
Author(s):  
Daniel R. Watson ◽  
Thomas Tan ◽  
Lori Wiseman ◽  
Gary M. Ansel ◽  
Chip Botti ◽  
...  
Keyword(s):  
Endovascular Repair ◽  
Abdominal Aortic Aneurysms ◽  
Aortic Aneurysms ◽  
Fiscal Impact ◽  
Abdominal Aortic

Updated Fiscal Impact Analysis, Naval Submarine Base, Kings Bay, Georgia

1986 ◽  
Author(s):  
William B. Moore ◽  
Robert A. Hutchinson ◽  
David D. Metcalf
Keyword(s):  
Impact Analysis ◽  
Fiscal Impact ◽  
Fiscal Impact Analysis ◽  
Kings Bay

The Fiscal Impact of Federalism in the United States

1947 ◽  
Vol 33 (4) ◽  
pp. 673
Author(s):  
Martin P. Claussen ◽  
James A. Maxwell
Keyword(s):  
United States ◽  
The United States ◽  
Fiscal Impact

Bargaining, Networks, and Management of Municipal Development Subsidies

2011 ◽  
Vol 42 (4) ◽  
pp. 481-497 ◽  
Author(s):  
Hyunsang Ha ◽  
Richard C. Feiock
Keyword(s):  
Economic Development ◽  
Political Institutions ◽  
Local Governments ◽  
Bargaining Power ◽  
Impact Analysis ◽  
Cost Benefit Analysis ◽  
Cost Benefit ◽  
Organizational Networks ◽  
Control Mechanisms ◽  
Fiscal Impact

This article investigates why cities use fiscal analyses such as cost–benefit analysis and/or fiscal impact analysis to manage offers of economic development incentives to business. We advance an approach to understanding economic development subsidies and control mechanisms that integrate political bargaining and network theories. Municipal bargaining power, institutional incentives, and organizational networks are hypothesized to influence development subsidy decisions. The results confirm that local governments’ bargaining power and political institutions influence the degree to which cities use fiscal analyses. In addition, public/private organizational networks that bridge public and private sectors by linking quasigovernmental organizations and local governments increase information and credibility thus leading to greater use of fiscal analyses.

Economic Evaluation of Changes in Reimbursement for Medications Purchased Through the 340B Drug Pricing Program

2019 ◽  
pp. 001857871988890
Author(s):  
Lauren A. Endriukaitis ◽  
Genevieve L. Hayes ◽  
Jason Mills
Keyword(s):  
South Carolina ◽  
Final Analysis ◽  
Medicare Beneficiaries ◽  
Drug Pricing ◽  
University Of South Carolina ◽  
Fiscal Impact ◽  
Worst Case ◽  
Original Intent ◽  
Reimbursement Scheme ◽  
Medical University

Background: The Centers for Medicare and Medicaid Services (CMS) implemented changes to the reimbursement scheme for 340B-acquired medications on January 1, 2018, reducing payments by approximately 25%. It was recognized that these changes would have a significant fiscal impact to Medical University of South Carolina (MUSC) Health. The purpose of this assessment was to review the financial impact of changes in Medicare reimbursement for clinic-administered medications. Methods: This study was a single-center, retrospective, financial evaluation of closed outpatient encounters for Medicare beneficiaries in calendar year 2018. Actual reimbursement was calculated for 2018. To better characterize the margin obtained, exploratory analyses were completed to identify best- and worst-case reimbursement outcomes. This exploratory analysis was conducted for both the new (ASP-22.5%) and old (ASP+6%) reimbursement schemes. Results: Overall, 10 973 encounters were reviewed for inclusion. Ultimately, 8028 encounters were included in the final analysis. Of all encounters, 88 unique medications were administered. Most of the drugs (55%) were associated with oncologic indications. An unfavorable variance was found in 3761 encounters (47%). The actual reimbursement margin for 2018 was $3 193 525. Conclusion: Changes to reimbursement outlined by the CMS at the start of 2018 resulted in decreased reimbursement for 340B-eligible, clinic-administered medications. Most of the unfavorable variances were associated with 340B acquisition prices that exceeded reimbursement. Although the original intent of the 340B Drug Pricing Program was to stretch federal resources, decreased payments could reduce institutional ability to fund programs that support medically vulnerable populations.

Sign in / Sign up

Export Citation Format

Share Document